293
Views
1
CrossRef citations to date
0
Altmetric
Retracted Article

RETRACTED ARTICLE: Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial

, , , ORCID Icon, , , , & ORCID Icon show all
Pages 1341-1350 | Received 12 Nov 2021, Accepted 17 Jun 2022, Published online: 12 Jul 2022
 

Statement of Retraction

We, the Editor and Publisher of the journal Expert Review of Anti-infective Therapy have retracted the following article:

Ahmed Hanei Elshafie, Hozaifa Khalil Elsawah, Mohamed Hammad, Eman Mohamed Sweed, Ahmed Salah Seif, Muhammad Mostafa Abdel Ghaffar, Feisal Mahmoud Goda, Esraa M Mosalam and Mahmoud S. Abdallah. Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial, Expert Review of Anti-infective Therapy, 2022;20(10):1341-1350, DOI: 10.1080/14787210.2022.2098113.

Following publication, concerns were raised regarding the integrity of the data and findings reported in the article. A subsequent investigation was conducted to provide an independent assessment of the data. The authors were cooperative and provided original data from the study to aid the assessment. The investigation found several errors with how the study was conducted and how the results were reported, leading to concerns over the reliability of the findings.

The Editor-in-Chief of the journal determined they no longer had confidence in the validity or integrity of the article and requested for the article to be retracted. The authors were notified of this and do not agree with this decision.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

View retraction statement:
Statement of Retraction: Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.